irbesartan / Generic mfg. - LARVOL DELTA

Adrenal artery embolization for bilateral primary aldosteronism (ENDO 2025) - "Both the captopril and saline tests failed to suppress aldosterone. For refractory bilateral primary aldosteronism, bilateral adrenal artery embolization lowers aldosterone levels and reduces antihypertensive medications as a palliative therapy without causing corticosteroid insufficiency."

Cardiovascular • Endocrine Disorders • Erectile Dysfunction • Hypertension • Palliative care • Renal Disease • CXCR4

START-or-NOT: Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU. (clinicaltrials.gov) - P3 | N=508 | Active, not recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Trial completion date: Jun 2027 ➔ Jun 2026 | Trial primary completion date: Jun 2026 ➔ Jun 2025 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Acute Kidney Injury • Nephrology • Renal Disease

Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials. (PubMed, JACC Heart Fail) - P3 | "In this participant-level pooled analysis of 4 large-scale HFpEF outcome trials, obesity and excess abdominal adiposity were highly prevalent. WC and WHtR were associated with an increased risk of kidney outcomes, while BMI was not. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213) (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711) (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function [TOPCAT]; NCT00094302) (Irbesartan in Heart Failure With Preserved Systolic Function [I-PRESERVE]; NCT00095238)."

Journal • Retrospective data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hepatology • Nephrology • Obesity • Renal Disease

Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX (ERA 2025) - P3 | "Clinically meaningful low proteinuria thresholds and partial and complete remission definitions were achieved earlier and more often with SPAR vs IRB. In DUPLEX, the risk of KF was lower among patients who achieved partial or complete remission of proteinuria vs those who did not. Taken together, results support the nephroprotective benefit of SPAR in patients with FSGS."

Clinical • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Renal Disease

Efficacy and safety of endothelin receptor antagonists in IgA nephropathy: A systematic review and meta-analysis of randomized controlled trials (ERA 2025) - "Endothelin receptor antagonists reduce UPCR in IgA patiens compared to placebo or Irbesartan, while were associated with increased risk of causing hypotension, anemia and dizziness. Additional evidence from large, well-designed randomized controlled trials and real-world research are urgently needed to ffurther clarify the efficacy and safety of ERAs."

Retrospective data • Review • Anemia • Glomerulonephritis • Hematological Disorders • Hypotension • IgA Nephropathy • Renal Disease

Effects of Sparsentan After Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients With IgA Nephropathy (IgAN) in the PROTECT Trial (ERA 2025) - "These data support the marked efficacy and tolerability of sparsentan in patients with IgAN who had previously received over 2 years of fully titrated maximum tolerated ARB therapy during the PROTECT trial."

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

Not Just an Itch: A Rare Dermatological Manifestation in Chronic Kidney Disease (ERA 2025) - "Her medical history includes long-standing hypertension treated with irbesartan, a surgically and endovascularly managed cerebral aneurysm in 2006, and a history of preeclampsia and HELLP syndrome during pregnancies (G5P5)...Current medications include esomeprazole, acetylsalicylic acid, sertraline, epoetin beta, folic acid, sevelamer, cinacalcet, cholecalciferol, calcitriol, and lactulose...The onset of the lesions coincided with the initiation of atorvastatin therapy, which was discontinued without clinical improvement...Treatment was started with acitretin 10 mg, allopurinol 100 mg, and emollients, resulting in initial improvement... This case underscores the importance of recognizing RPC as a rare but clinically significant skin disorder, particularly in patients with systemic illnesses like CKD. While uncommon, its association with systemic diseases highlights the need for a multidisciplinary approach. After excluding potential drug-induced causes, a skin biopsy..."

Autosomal Dominant Polycystic Kidney Disease • Cardiovascular • Chronic Kidney Disease • Dermatology • Diabetes • Diabetic Nephropathy • Genetic Disorders • Gynecology • Hypertension • Metabolic Disorders • Mood Disorders • Nephrology • Oncology • Polycystic Kidney Disease • Pruritus • Renal Disease • Vascular Neurology

Clinical Practice Gaps in the Diagnosis and Management of Immunoglobulin A Nephropathy (ERA 2025) - " •395 nephrologists completed all questions within the data collection timeframe •76% of nephrologists saw between 1 and 10 patients per month with IgAN •38% failed to recognise that the RaDaR study showed that IgAN is progressive even in patients thought to be at low risk (proteinuria < 1 g/d) •17% could not correctly identify that the most common clincial presentation of IgAN is asymptomatic microscopic hematuria and proteinuria •44% did not recognise the presence of tubular atrophy (T), a finding of the MEST-C score, is a consistent, independent predictor of worse outcomes in patients with IgAN •34% did not identify the correct order of the multihit hypothesis of the pathophysiology of IgAN •Only 21% knew that production of Gd-IgA1 is a mechanism via which the cytokines a proliferation inducing ligand (APRIL) and B-cell activating factor (BAFF) drive IgAN pathogenesis •66% did not recognise that, according to 2021 KDIGO guidelines, considering enrollment in a..."

Clinical • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Renal Disease

Implications of proteinuria remission on estimated glomerular filtration rate (eGFR) trajectory in patients with IgA nephropathy in the PROTECT trial (UKKW 2025) - "Background : In PROTECT, sparsentan (SPAR) reduced proteinuria and increased the proportion of patients achieving complete proteinuria remission (CR; urine protein excretion [UPE] <0.3 g/day) (31%) vs irbesartan (IRB) (11%). In IgAN, achievement of low proteinuria is strongly predictive of better long-term kidney function. eGFR preservation was more evident in patients who achieved low proteinuria vs those who did not; notably, in patients who achieved CR, the mean rate of kidney function decline (eGFR chronic slope) was <1.0 mL/min/1.73 m2/year. As SPAR-treated patients achieved proteinuria remission more frequently vs IRB in PROTECT, this analysis further supports the benefit of SPAR for long-term preservation of kidney function."

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

Concomitant sparsentan (SPAR) and SGLT2 inhibitors in patients with IgA nephropathy in the PROTECT open-label extension (OLE) (UKKW 2025) - "Background : SPAR, a non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA), demonstrated superior efficacy for proteinuria reduction and better preservation of kidney function vs irbesartan in patients with Immunoglobulin A nephropathy (IgAN) in the PROTECT trial. These data show that an SGLT2i added to a stable dose of SPAR is generally well tolerated and may lead to further reductions in proteinuria. The safety and efficacy of sparsentan with or without concomitant SGLT2i treatment are also being investigated in a separate randomised sub-study within the PROTECT OLE."

Clinical • Cardiovascular • Glomerulonephritis • Hypertension • Hypotension • IgA Nephropathy • Infectious Disease • Novel Coronavirus Disease • Renal Disease

Effects of antihypertensive drugs on the metabolism of mobocertinib in rats both in vitro and in vivo. (PubMed, Drug Metab Dispos) - "The inhibitory mechanism of mobocertinib was further investigated for nicardipine, irbesartan, telmisartan, carvedilol, prazosin hydrochloride, and spironolactone. In this study, the most common antihypertensive drugs were found to inhibit the metabolism of mobocertinib in vitro. We found that benidipine, nicardipine, telmisartan, and irbesartan inhibited the metabolism of mobocertinib in vitro and in vivo."

Journal • Preclinical

Pharmaceuticals in coastal sediments: validation of a Ultra-High-Performance Liquid Chromatography coupled with Time-of-Flight Mass Spectrometry (UHPLC-TOF-MS) methodology. (PubMed, Environ Pollut) - "Recovery values at the LOD level ranged from 74.3 % for irbesartan to 115.4% for indapamide, while repeatability and reproducibility were under 19.5 % and 29.2%, respectively. All performance criteria met the requirements outlined in European guidelines. To evaluate the method's robustness, it was applied to 12 sediment samples collected from an estuary, with irbesartan detected in 5 samples."

Journal

Protective effects of irbesartan against neurodegeneration in APP/PS1 mice: Unraveling its triple anti-apoptotic, anti-inflammatory and anti-oxidant action. (PubMed, Biomed Pharmacother) - "These effects were accompanied by a marked reduction in oxidative stress and neuroinflammation. Overall, these results support the potential of intranasal irbesartan as a promising multi-target therapeutic strategy for AD, capable of modulating key pathological features, including synaptic dysfunction, mitochondrial dysfunction, oxidative stress, apoptosis, and neuroinflammation."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Inflammation • Metabolic Disorders • HMOX1

Sodium Glucose Cotransporter 2 Inhibitor (SGLTI) use in a Pediatric Patient Receiving Cisplatin (ASPHO 2025) - " We report a case of an adolescent male diagnosed with a high-risk metastatic testicular germ cell tumor, treated extensively with CP, bleomycin, and etoposide for 10 months in attempt to induce remission...He required irbesartan up to 300 mg daily for hypertension. Dapagliflozin, an SGLT2i, (10mg/day) was started 3 months into treatment...Our patient's GFR stabilized at 60 ml/min/1.73 m2 (CKiD U25), allowing him to continue CP therapy along with carboplatin for SCT (cumulative dose >60mg/m2)... This case highlights an important potential of the SGLT2i in pediatric oncology for CP-induced nephrotoxicity and hypomagnesemia. Our report was not designed prospectively and despite numerous confounding factors, we found the SGLT2i stabilized our patient's kidney function and Mg loss despite extensive treatment with CP."

Clinical • Acute Kidney Injury • Cardiovascular • Germ Cell Tumors • Hypertension • Nephrology • Oncology • Pediatrics • Renal Disease • Septic Shock • Testicular Cancer

Comparison of Adverse Events Among Angiotensin Receptor Blockers in Hypertension Using the United States Food and Drug Administration Adverse Event Reporting System. (PubMed, Cureus) - "Results Using losartan as the reference, valsartan, irbesartan, candesartan, telmisartan, and olmesartan demonstrated significantly lower RPs for skin disorders. Conversely, patients with elevated cardiovascular risk may require closer monitoring when prescribed valsartan, including more frequent follow-up visits or additional cardiovascular diagnostics to detect early AEs. These findings enable healthcare providers to tailor ARB selection and monitoring strategies to optimize efficacy and safety in hypertension treatment."

Adverse events • Journal • Cardiovascular • Dermatology • Hypertension • Hypotension

Changes in blood pressure, medication adherence, and cardiovascular-related health care use associated with the 2018 angiotensin receptor blocker recalls and drug shortages among patients with hypertension. (PubMed, J Manag Care Spec Pharm) - "One of the largest-ever retail drug shortages began in 2018 when several angiotensin II receptor blockers (ARBs) for treating hypertension, heart failure, and chronic kidney disease-valsartan, losartan, and irbesartan-were recalled for carcinogenic impurities. Although overall impacts on clinical outcomes were minimal and not statistically significant, small increases in medication gaps and MACE-related acute care visits among some patients occurred after more than 1 year. The ARB recalls may have been associated with fewer adverse events than other recent shortages owing to the widespread availability of alternative treatments in the same or similar drug class."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology • Renal Disease

Risk Assessment of Micropollutants for Human and Environmental Health: Alignment with the Urban Wastewater Treatment Directive in Southeastern Spain. (PubMed, Toxics) - "The risk assessment identified a low risk for most compounds regarding human health, except for citalopram (HRQ = 19.116) and irbesartan (HRQ = 1.104), which showed high human risk quotients (HQR > 1) in babies, particularly in reclaimed water. In terms of ecotoxicological risk, irbesartan presented the highest ecological risk quotient (ERQ = 3.500) in fish, followed by clarithromycin, with algae (ERQ = 1.500) being the most vulnerable organism. Furthermore, compounds like citalopram, venlafaxine, and benzotriazole exhibited moderate ecological risks (ERQ between 0.1 and 1) in the reclaimed water, and their risk was reduced in surface water and groundwater. Finally, this study discussed the potential impacts of elevated concentrations of these emerging compounds, emphasizing the need for rigorous wastewater monitoring to protect human health and ecosystem integrity. It also revealed notable differences in risk assessment outcomes when comparing two distinct evaluation..."

Journal

Angiotensin receptor blockers and drug-induced liver injury: a cohort study using electronic-health records-based common data model database (EASL 2025) - "In this study, patients were designated to treatment groups according to the ARB prescribed at cohort entry, i.e., azilsartan, eprosartan, telmisartan, fimasartan, valsartan, olmesartan, losartan, irbesartan, or candesartan. Our findings provide insights to the methods for detecting DILI using real-world data and enhance understanding of the variations in risk of DILI among individuals using different ARBs."

Hepatology • Liver Failure

Sodium Glucose Cotransporter 2 inhibitor (SGLT2i) Use in a Pediatric Patient Receiving Cisplatin (PAS 2025) - "Design/ We report a case of an adolescent male diagnosed with a high-risk metastatic testicular germ cell tumor, treated extensively with CP, bleomycin, and etoposide for 10 months in attempt to induce remission...He required irbesartan up to 300 mg daily for hypertension. Dapagliflozin, an SGLT2i, (10mg/d) was started 3 months into treatment... Our patient’s GFR stabilized at 60 ml/min/1.73 m²(CKiD U25), allowing him to continue CP therapy along with carboplatin for SCT (cumulative dose >60mg/m2). (Figure1). With the addition of the SGLT2i, he discontinued IV Mg supplementation while maintaining adequate Mg levels on oral Mg-Protein-Complex (Figure 3)."

Clinical • Acute Kidney Injury • Bone Marrow Transplantation • Cardiovascular • Germ Cell Tumors • Hypertension • Nephrology • Oncology • Pediatrics • Renal Disease • Septic Shock • Testicular Cancer

Sacubitril-Valsartan Lowers Blood Pressure in Patients on Dialysis: A Randomized Controlled Multicenter Study. (PubMed, Kidney Dis (Basel)) - "This randomized, controlled, multicenter study, conducted across 10 hospitals, aimed to compare the effectiveness and safety of sacubitril-valsartan versus irbesartan in managing hypertension among dialysis patients. In dialysis patients with hypertension, especially those undergoing HD, ARNI demonstrated superior effectiveness in reducing BP compared to ARB. The safety profiles of both treatments were comparable and acceptable."

Clinical • Journal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease • NPPB

Comparison of Sparsentan and Irbesartan in FSGS (DocWire) - P3 | N=371 | DUPLEX (NCT03493685) | Sponsor: Travere Therapeutics, Inc. | "The DUPLEX trial (NCT03493685) determined that the dual endothelin angiotensin receptor antagonist sparsentan resulted in sustained proteinuria reduction among patients with focal segmental glomerulosclerosis (FSGS). Researchers sought further insights by comparing the effects of sparsentan and irbesartan on proteinuria remission and assessed how achieving complete or partial remission affected progression to kidney failure. Results were presented at the National Kidney Foundation Spring Clinical Meetings 2025....Patients with FSGS received sparsentan 800 mg/d (n=184) or irbesartan 300 mg/d (n=187) during the phase 3, 108-week trial. The study end points included proteinuria partial remission (urine protein-to-creatinine ratio [UPCR] ≤1.5 g/g and >40% reduction from baseline) or complete remission (UPCR <0.3 g/g)."

P2 data • Focal Segmental Glomerulosclerosis

Patients (Pts) in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB): Implications for Slowing Progression to Kidney Failure (KF) in Focal Segmental Glomerulosclerosis (FSGS) (NKF-SCM 2025) - P3 | "SPAR was generally well tolerated, with no new safety concerns.Conclusion Pts with FSGS achieved PR and CR more rapidly and with higher incidence with SPAR vs IRB. Pts who reached PR or CR showed markedly reduced risk of progression to KF vs those who did not, supporting the nephroprotective benefit of SPAR in FSGS."

Clinical • Late-breaking abstract • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Renal Disease

Improving Proteinuria With Sparsentan (SPAR) in Patients (Pts) With IgA Nephropathy (IgAN): A Case Series (NKF-SCM 2025) - "In the PROTECT trial, SPAR reduced proteinuria and led to complete proteinuria remission (CR) more often vs maximum labeled dose irbesartan; SPAR was well tolerated, with 95% of pts titrated to the target dose (400 mg/d).Methods Five pts with biopsy-proven IgAN (aged ≈35-65 y) received SPAR (treatment duration, 4-12 mo). SPAR was generally well tolerated. In 2 pts with intolerance to the 400-mg/d dose, dose reduction to 200 mg/d was well tolerated without diminished effectiveness (both pts achieved UPCR <0.5 g/g; 1 achieved <0.3 g/g).Conclusion This case series supports the benefit of SPAR on achieving low proteinuria in pts with IgAN, irrespective of UPCR and eGFR at initiation or treatment history."

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

Raspberry ameliorates renal fibrosis in rats with chronic kidney disease via the PI3K/Akt pathway. (PubMed, Phytomedicine) - "Raspberry was firstly discovered to potentially treat CKD by alleviating renal fibrosis through inhibition of the PI3K/AKT pathway. Raspberry, as a medicinal and edible traditional herb, could serve as a promising therapeutic agent or health supplement for improving renal fibrosis and slowing CKD progression."

Journal • Preclinical • Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

A comparative study of gellan gum and xanthan gum versus commercial vehicles as pharmaceutical thickening agents in oral suspensions. (PubMed, Eur J Pharm Biopharm) - "Rheological behaviour, sedimentation and resuspension of vehicles were studied with and without irbesartan used as a model insoluble drug...We show that the high-acyl gellan gum vehicle offers the best viscosity and stability results for use in pharmaceutical suspensions because it exhibits stable homogeneity and viscosity in time, regardless of storage temperature, and is compatible with safe administration in dysphagic patients after 90 days. High-acyl gellan gum appears to be a good suspending agent for pharmaceutical suspensions."

Clinical • Journal • Gastrointestinal Disorder